Article ; Online: Die Prävalenz von SARS-CoV-2-IgG-AK liegt bei 1,2% : Screening bei asymptomatischen ambulanten Patienten.
2020 Volume 162, Issue 14, Page(s) 44–46
Abstract: Patients with newly diagnosed COVID-19 (coronavirus disease 2019) develop antibodies against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2). To date, few data have been obtained of the prevalence of SARS-CoV-2-antibodies in general ... ...
Title translation | The prevalence rate of anti-SARS-CoV-2-IgG is 1.2% - Screening in asymptomatic outpatients in Germany (Northrhine-Westfalia). |
---|---|
Abstract | Patients with newly diagnosed COVID-19 (coronavirus disease 2019) develop antibodies against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2). To date, few data have been obtained of the prevalence of SARS-CoV-2-antibodies in general population and in asymptomatic outpatients in Germany.From March 26 to June 4 2020, 415 asymptomatic outpatients were tested prospectively in Northrhine-Westfalia (Germany), to detect SARS-CoV-2-IgG-antibodies. In case of a positive result, anti-SARS-CoV-2-IgA was determined additionally.5 of 415 asymptomatic outpatients had positive SARS-CoV-2-IgG-antibodies with a calculated prevalence of 1.2%. Reference range of anti-SARS-CoV-2-IgA and IgG was defined as ratio for negative < 0.8, borderline 0.8-1.1 and > 1.1 positive. The mean concentration of SARS-CoV-2-IgG-antibodies of the positive 5 outpatients was lower than in symptomatic patients with COVID-19 (n = 12) and positive PCR of SARS-CoV-2 (3.04 ± 2.58 versus 8.05 ± 6.70; p = 0.002). 4 of 5 patients had elevated SARS-CoV-2-IgA-antibodies (1.61 ± 0.82). In 408 screening-outpatients with negative anti-SARS-CoV-2-ELISA-IgG (< 0.8), the mean ratio was 0.25 ± 0.13. Two patients were in the borderline range (0.83 and 0.86).The prevalence of 1.2% of SARS-CoV-2-IgG-antibodies and consequently the rate of infection in asymptomatic outpatients in Northrhine-Westfalia (Germany) is low. The impact of virus neutralisation by antibodies and consequently immunization is the challenge of further investigations. |
MeSH term(s) | Antibodies, Viral/blood ; Asymptomatic Infections ; Betacoronavirus ; COVID-19 ; Coronavirus Infections/diagnosis ; Germany ; Humans ; Immunoglobulin A/blood ; Immunoglobulin G/blood ; Outpatients ; Pandemics ; Pneumonia, Viral/diagnosis ; Prevalence ; SARS-CoV-2 |
Chemical Substances | Antibodies, Viral ; Immunoglobulin A ; Immunoglobulin G |
Keywords | covid19 |
Language | German |
Publishing date | 2020-08-11 |
Publishing country | Germany |
Document type | Journal Article ; Review |
ZDB-ID | 1478211-x |
ISSN | 1613-3560 ; 1438-3276 |
ISSN (online) | 1613-3560 |
ISSN | 1438-3276 |
DOI | 10.1007/s15006-020-0750-y |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Ua VI Zs.20: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
|||
Zs.MG 72: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.